NANETS Consensus Statements/Guidelines Survey 2026

NANETS Guidelines Committee is actively involved in the development of consensus statements/guidelines to support the management of NET disease. Consensus statements/guidelines are developed using rigorous literature review and serve as important references for practicing physicians.

Currently, panels are working on developing consensus statements/guidelines regarding:

Localized gastric-duodenal NETs, in collaboration with ASGE
Surgical and Liver-directed Management of Patients with Neuroendocrine Liver Metastasis (NETLM): A Multi-Society Consensus
ACC
Appendiceal NETs guidelines
Midgut NETs(2 separate guidelines, one surgical and one systemic therapy)

Recently published guidelines:

NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumor
Clinical practice guideline and review of current evidence for biomarkers to inform therapeutic decision making in the care of patients with GEPNETs”, in collaboration with CommNETS
Practical Considerations when Providing Palliative Care to Patients with Neuroendocrine Tumors in the Context of Routine Disease Management or Hospice Care
Management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms
Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma
Diagnosis and Management of Patients with Lung Neuroendocrine Tumors

The full compendium of completed guidelines is available HERE.

The committee is seeking NANETS' member feedback on the work that has been done and on what the next set of consensus statements/guidelines might be. Please indicate the top 3 topics you consider of interest from the ones listed below, and/or submit additional topics of interest for future consensus statements/guidelines.

Thank you for taking part in this important survey.

Boris Naraev, MD, PhD, FACP

Chair, Guidelines Committee

Tanaz Vaghaiwalla, MD
Co-Chair

Question Title

1. Do you feel any of the current guidelines need updating? If so, which ones? (Use the link above to review the current guidelines.)

Multi-Society Consensus, “Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs”, in collaboration with CommNETS (2024)

Practical Considerations when providing Palliative Care to patients with Neuroendocrine Tumors in the context of routine disease management or hospice care (2023)

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms (2023)

Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma (2021)

CommNETS/NANETS Guidelines for the Diagnosis and Management of Patients With Lung NETs: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines (2021)

Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors (2020)

Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors (2020)

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (2020)

NANETS/SNMMI Procedure Standard for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate (2019)

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society (2017)

Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors (2017)

(Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors (2017)

Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors (2013)

The North American Neuroendocrine Tumor Society (NANETS) Guidelines: Mission, Goals, and Process (2010)

NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumor (2026)

Why?

Question Title

2. Please rank your level of interest in each of the following guidelines topics: (Required.)

Question Title

3. Additional topic proposals and comments

Question Title

4. Name and Email

Name

Institution

Email Address

NANETS Consensus Statements/Guidelines Survey 2026

Question Title

* 1. Do you feel any of the current guidelines need updating? If so, which ones? (Use the link above to review the current guidelines.)

Question Title

* 2. Please rank your level of interest in each of the following guidelines topics: (Required.)

Question Title

* 3. Additional topic proposals and comments

Question Title

* 4. Name and Email

1. Do you feel any of the current guidelines need updating? If so, which ones? (Use the link above to review the current guidelines.)

2. Please rank your level of interest in each of the following guidelines topics: (Required.)

3. Additional topic proposals and comments

4. Name and Email